1. Home
  2. Analysis
  3. Exjade
  4. Tumor

Exjade and Tumor - a phase IV clinical study of FDA data

Summary:

Tumor is reported as a side effect among people who take Exjade (deferasirox), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Vitamin B12, and have Myelodysplastic syndrome.

The phase IV clinical study analyzes which people have Tumor when taking Exjade. It is created by eHealthMe based on reports of 29,418 people who have side effects when taking Exjade from the FDA, and is updated regularly.

What is Exjade?

Exjade has active ingredients of deferasirox. It is often used in iron overload. eHealthMe is studying from 29,456 Exjade users. Check the latest studies of Exjade.

What is Tumor?

Tumor is found to be associated with 1,418 drugs and 1,704 conditions by eHealthMe. Check the latest studies of Tumor.

On Jul, 13, 2026

29,418 people reported to have side effects when taking Exjade.
Among them, 71 people (0.24%) have Tumor.

Could Exjade cause Tumor?

Among these 71 people:

How long have people been on Exjade when they have Tumor? *

  • < 1 month: 15.38 %
  • 1 - 6 months: 23.08 %
  • 6 - 12 months: 30.77 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 23.08 %
  • 5 - 10 years: 7.69 %
  • 10+ years: 0.0 %

What is the gender of people who have Tumor when taking Exjade? *

  • female: 64.71 %
  • male: 35.29 %

What is the age of people who have Tumor when taking Exjade? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 5.13 %
  • 20-29: 2.56 %
  • 30-39: 15.38 %
  • 40-49: 17.95 %
  • 50-59: 10.26 %
  • 60+: 48.72 %

What are other drugs people take besides Exjade? *

  1. Lasix: 8 people, 11.27%
  2. Vitamin B12: 8 people, 11.27%
  3. Jadenu: 7 people, 9.86%
  4. Celexa: 6 people, 8.45%
  5. Magnesium: 6 people, 8.45%
  6. Ditropan: 6 people, 8.45%
  7. Desferal: 5 people, 7.04%
  8. Amlodipine: 4 people, 5.63%
  9. Hydrea: 4 people, 5.63%
  10. Dipyrone: 3 people, 4.23%

What are other side effects people have besides Tumor? *

  1. Malaise (a feeling of general discomfort or uneasiness): 29 people, 40.85%
  2. Fatigue (feeling of tiredness): 21 people, 29.58%
  3. Abdominal Pain Upper: 21 people, 29.58%
  4. Weight Decreased: 20 people, 28.17%
  5. Haemoglobin Decreased: 18 people, 25.35%
  6. Diarrhea: 18 people, 25.35%
  7. Drug Intolerance (drug sensitivity): 16 people, 22.54%
  8. Gait Disturbance: 16 people, 22.54%
  9. Blood Iron Increased: 16 people, 22.54%
  10. Urinary Tract Infection: 15 people, 21.13%

What are the existing conditions these people have? *

  1. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 20 people, 28.17%
  2. High Blood Pressure: 7 people, 9.86%
  3. Urinary Tract Infection: 6 people, 8.45%
  4. Brain Neoplasm (tumour of brain): 6 people, 8.45%
  5. Colitis (inflammation of colon): 6 people, 8.45%
  6. Pain: 5 people, 7.04%
  7. Primary Myelofibrosis (primary disorder of the bone marrow): 4 people, 5.63%
  8. Diabetes: 3 people, 4.23%
  9. Cardiac Disorder: 2 people, 2.82%
  10. Blood Disorder: 2 people, 2.82%

* Approximation only. Some reports may have incomplete information.

Do you take Exjade and have Tumor?

- Check whether Tumor is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Exjade:

Tumor treatments and more:

How severe was Tumor and when was it recovered:

Expand to all the drugs that have ingredients of deferasirox:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Exjade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tumor:

Browse all the conditions that are associated with Tumor:

  • Tumor (1,704 conditions)

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on deferasirox (the active ingredients of Exjade) and Exjade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.